Drug Trial Radar · NCT07947940
Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With Tafamidis
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1
Planned (sponsor's estimate)
Start
Nov 24, 2026
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.
Conditions
- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Interventions
TafamidisDrug
As provided in real-world routine clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to All cause MortalityTime frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
- Time to Cardiovascular Mortality (CV)Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
- Time to First (Cardiovascular, Non-Cardiovascular) HospitalizationTime frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019-June 30, 2026)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.